1. Clinical effects of metoprolol in obstructive hypertrophic cardiomyopathy (TEMPO). A randomized, double-blinded, placebo-controlled crossover trial. (14th October 2021) Authors: Dybro, A M; Rasmussen, T B; Nielsen, R R; Andersen, M J; Jensen, M K; Poulsen, S H Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Differentiation between Bernard-Soulier syndrome and immune thrombocytopenia by immunostaining of peripheral blood. Issue 12 (December 1989) Authors: Poulsen, L O; Johansen, P; Jensen, M K; Freund, L Journal: Journal of clinical pathology Issue: Volume 42:Issue 12(1989) Page Start: 1296 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Metoprolol improves left ventricular longitudinal function at rest and during exercise in obstructive hypertrophic cardiomyopathy. (3rd October 2022) Authors: Dybro, A; Rasmussen, T B; Nielsen, R R; Pedersen, A L D; Andersen, M J; Jensen, M K; Poulsen, S H Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Temporal trends, characteristics and comorbidities of patients with hypertrophic cardiomyopathy in Denmark from 2005 to 2018: a nationwide cohort study. (3rd October 2022) Authors: Zoerner, C R; Pallisgaard, J L; Schjerning, A M; Toennesen, J; Jensen, M K; Gislason, G; Hansen, M L Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗